Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 2
2020 3
2021 5
2022 3
2023 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Type 2 diabetes and heart failure: insights from the global DISCOVER study.
Arnold SV, Khunti K, Bonnet F, Charbonnel B, Chen H, Cid-Ruzafa J, Cooper A, Fenici P, Gomes MB, Hammar N, Ji L, Luporini-Saraiva G, Medina J, Nicolucci A, Ramirez L, Shestakova MV, Shimomura I, Surmont F, Tang F, Vora J, Watada H, Kosiborod M; DISCOVER investigators. Arnold SV, et al. ESC Heart Fail. 2021 Apr;8(2):1711-1716. doi: 10.1002/ehf2.13235. Epub 2021 Feb 11. ESC Heart Fail. 2021. PMID: 33570253 Free PMC article.
Impact of micro- and macrovascular complications of type 2 diabetes on quality of life: Insights from the DISCOVER prospective cohort study.
Arnold SV, Khunti K, Tang F, Chen H, Nicolucci A, Gomes MB, Ji L, Shestakova MV, Watada H, Cooper A, Fenici P, Hammar N, Medina J, Kosiborod M; DISCOVER investigators. Arnold SV, et al. Endocrinol Diabetes Metab. 2022 Mar;5(2):e00321. doi: 10.1002/edm2.321. Epub 2022 Jan 14. Endocrinol Diabetes Metab. 2022. PMID: 35029066 Free PMC article.
Prevalence and progression of chronic kidney disease among patients with type 2 diabetes: Insights from the DISCOVER study.
Khunti K, Charbonnel B, Chen H, Cherney DZ, Cooper A, Fenici P, Gomes MB, Hammar N, Heerspink HJL, Ji L, Medina J, Nicolucci A, Ramirez L, Rathmann W, Shestakova MV, Shimomura I, Tang F, Watada H, Kosiborod M; DISCOVER Investigators. Khunti K, et al. Diabetes Obes Metab. 2021 Aug;23(8):1956-1960. doi: 10.1111/dom.14401. Epub 2021 May 3. Diabetes Obes Metab. 2021. PMID: 33852196
Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second-line glucose-lowering therapy: The global DISCOVER study.
Charbonnel BH, Chen H, Cid-Ruzafa J, Cooper A, Fenici P, Gomes MB, Saraiva GL, Medina J, Nicolucci A, Shestakova MV, Shimomura I, Surmont F, Tang F, Vora J, Watada H, Khunti K; DISCOVER Investigators. Charbonnel BH, et al. Diabetes Obes Metab. 2023 Jan;25(1):46-55. doi: 10.1111/dom.14842. Epub 2022 Sep 16. Diabetes Obes Metab. 2023. PMID: 36111434 Free PMC article.
Quality of life in people with type 2 diabetes in the 3 years following initiation of second-line therapy: The DISCOVER study.
Nicolucci A, Chen H, Cooper A, Fenici P, Gomes MB, Hammar N, Ji L, Khunti K, Kosiborod M, Medin J, Shestakova MV, Shimomura I, Tang F, Vora J, Watada H, Arnold SV; DISCOVER investigators. Nicolucci A, et al. Diabetes Res Clin Pract. 2022 Mar;185:109218. doi: 10.1016/j.diabres.2022.109218. Epub 2022 Jan 31. Diabetes Res Clin Pract. 2022. PMID: 35114299
Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study.
Gomes MB, Rathmann W, Charbonnel B, Khunti K, Kosiborod M, Nicolucci A, Pocock SJ, Shestakova MV, Shimomura I, Tang F, Watada H, Chen H, Cid-Ruzafa J, Fenici P, Hammar N, Surmont F, Ji L; DISCOVER investigators. Gomes MB, et al. Diabetes Res Clin Pract. 2019 May;151:20-32. doi: 10.1016/j.diabres.2019.03.024. Epub 2019 Mar 20. Diabetes Res Clin Pract. 2019. PMID: 30904743 Free article.
Socioeconomic factors associated with hypoglycaemia in patients starting second-line glucose-lowering therapy: The DISCOVER study.
Rathmann W, Charbonnel B, Gomes MB, Hammar N, Khunti K, Kosiborod M, Kuss O, Shestakova MV, Watada H, Shimomura I, Tang F, Cid-Ruzafa J, Chen H, Fenici P, Surmont F, Ji L; DISCOVER investigators. Rathmann W, et al. Diabetes Res Clin Pract. 2020 Jul;165:108250. doi: 10.1016/j.diabres.2020.108250. Epub 2020 Jun 10. Diabetes Res Clin Pract. 2020. PMID: 32531326
Health-related quality of life in patients with type 2 diabetes initiating a second-line glucose-lowering therapy: The DISCOVER study.
Nicolucci A, Chen H, Cid-Ruzafa J, Cooper A, Fenici P, Gomes MB, Hammar N, Khunti K, Kosiborod M, Leigh P, Medin J, Rathmann W, Shestakova MV, Shimomura I, Siddiqui A, Tang F, Watada H, Ji L; DISCOVER investigators. Nicolucci A, et al. Diabetes Res Clin Pract. 2021 Oct;180:108974. doi: 10.1016/j.diabres.2021.108974. Epub 2021 Jul 22. Diabetes Res Clin Pract. 2021. PMID: 34302913
Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme.
Khunti K, Chen H, Cid-Ruzafa J, Fenici P, Gomes MB, Hammar N, Ji L, Kosiborod M, Pocock S, Shestakova MV, Shimomura I, Tang F, Watada H, Nicolucci A; DISCOVER investigators. Khunti K, et al. Diabetes Obes Metab. 2020 Jan;22(1):66-78. doi: 10.1111/dom.13866. Epub 2019 Oct 1. Diabetes Obes Metab. 2020. PMID: 31468637 Free PMC article.
Associations between second-line glucose-lowering combination therapies with metformin and HbA1c, body weight, quality of life, hypoglycaemic events and glucose-lowering treatment intensification: The DISCOVER study.
Khunti K, Charbonnel B, Cooper A, Gomes MB, Ji L, Leigh P, Nicolucci A, Rathmann W, Shestakova MV, Siddiqui A, Tang F, Watada H, Chen H; DISCOVER investigators. Khunti K, et al. Diabetes Obes Metab. 2021 Aug;23(8):1823-1833. doi: 10.1111/dom.14400. Epub 2021 May 3. Diabetes Obes Metab. 2021. PMID: 33852202
13 results